Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

ClinicalTrials.gov ID: NCT07563881

Public ClinicalTrials.gov record NCT07563881. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

Study identification

NCT ID: NCT07563881
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Rapport Therapeutics Inc.; Industry
Enrollment: 333 participants

Conditions and interventions

Conditions

Interventions

RAP-219 Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 4, 2026
Primary completion: Jun 30, 2029
Completion: Aug 31, 2029
Last update posted: Aug 31, 2026

2026 – 2029

United States locations

U.S. sites: 11
U.S. states: 11
U.S. cities: 11

Facility	City	State	ZIP	Site status
Amicis Research Center	Palmdale	California	91324	Recruiting
Panhandle Research and Medical Clinic, LLC	Gulf Breeze	Florida	32561	Recruiting
Emory Brain Health Center	Atlanta	Georgia	30329	Recruiting
Consultants in Epilepsy & Neurology, PLLC	Boise	Idaho	83702	Recruiting
Indiana University Health Fort Wayne Neurology	Fort Wayne	Indiana	46804	Recruiting
Mid-Atlantic Epilepsy and Sleep Center	Bethesda	Maryland	20817	Recruiting
Northeast Regional Epilepsy Group	Hackensack	New Jersey	07601	Recruiting
Asheville Neurology Specialists	Asheville	North Carolina	28806	Recruiting
Cleveland Clinic	Cleveland	Ohio	44109	Recruiting
Thomas Jefferson University	Philadelphia	Pennsylvania	19107	Recruiting
Neurological Associates	Richmond	Virginia	23236	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07563881, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 31, 2026 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07563881 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →